What we've updated — dated and sourced.

April 28, 2026

• New peptide reference entry: KLOW peptide blend — current search-market term for a non-standardized BPC-157 + TB-500 + GHK-Cu + KPV blend. Includes KLOW 80 vial arithmetic, component-by-component links, KLOW vs Klotho peptide disambiguation, and FDA 503A context after the April 22, 2026 update.
• Peptide index, sitemap, and llms.txt updated so search crawlers and AI agents can discover the KLOW entry directly from the reference hub and structured site surfaces.

April 24, 2026

• 5 new peptide reference entries added to the reference library: GHK-Cu, Ipamorelin, CJC-1295 (with DAC), Tesamorelin (Egrifta / Egrifta WR), and Sermorelin (Geref). All with mechanism, pharmacokinetics, FDA status, and reconstitution math.
• New public pages: Press & Brand (brand disambiguation + media contact) and this Changelog.
• Homepage FAQ section and FAQPage schema added, covering brand-intent questions about what Enhanced Health is, what it tracks, pricing, platforms, and medical-advice scope.
• Organization schema updated with alternateName (Enhanced Health AI, enhancedhealth.ai), App Store sameAs link, and separate contact points for support, media, and privacy.
• Email split: [email protected] added for GDPR / CCPA data-access and data-deletion requests; [email protected] added as the direct media / corrections contact.
• Google Search Console: Domain property verified for enhancedhealth.ai; sitemap resubmitted; priority indexing requested for homepage, peptides hub, BPC-157, semaglutide, tirzepatide, /vs/, KPV, GHK-Cu, and tesamorelin.
• IndexNow resubmission to Bing / Yandex / ChatGPT-backed search for all 22+ URLs now in the sitemap.

April 22, 2026

• New peptide reference entry: KPV (Lys-Pro-Val) — C-terminal tripeptide of α-MSH, PepT1-mediated uptake, NF-κB and MAP kinase inhibition, preclinical IBD evidence. Covers the FDA's April 15, 2026 503A Category 2 removal and the July 23, 2026 PCAC meeting for KPV-related bulk drug substances.
• Regulatory updates propagated to TB-500 and MOTS-c to reflect the April 15, 2026 503A Category 2 removal and scheduled PCAC consultation.
• /vs/ comparison hub expanded with additional current competitors (Vialr, InjectionLog, PepTrac, PeptIQ, Shotlee, PepMinder) and bias-disclosed head-to-head framing.
• Image optimization shipped — responsive 420w/720w screenshot variants plus a hero-image preload hint for Core Web Vitals.
• Cloudflare Worker added to canonicalize www.enhancedhealth.ai to the apex via 301 redirect.
• About and Editorial pages added: /about/ for product scope, /editorial/ for source standards, review process, AI-drafting disclosure, and corrections policy.

April 22, 2026 — initial reference library launch

• First seven peptide reference entries published: BPC-157, semaglutide, tirzepatide, retatrutide (LY3437943), TB-500, MOTS-c, and SS-31 (elamipretide / FORZINITY).
• Consistent entry structure adopted across every peptide page: summary card, mechanism with citations, pharmacokinetics, storage, reconstitution math, FAQ, primary references.
• FAQPage, MedicalWebPage, and BreadcrumbList JSON-LD shipped on all reference pages.
• Initial sitemap.xml and llms.txt published. IndexNow endpoint notified for all URLs.

April 21, 2026 — Enhanced Health app goes live

• Enhanced Health v1 shipped on the iOS App Store — peptide protocol scheduling, dose and injection log, vial inventory, lab marker trend review with on-device OCR, Apple Health overlay, and PDF export.
• enhancedhealth.ai goes live as the marketing and reference surface for the app. Local-first privacy posture set: optional HealthKit, optional iCloud sync, no advertising SDKs, no sale of personal information, no cross-app tracking.

Update cadence

This changelog is updated whenever a material change ships — new peptide entries, regulatory updates that affect existing entries, structural site changes, app version releases, or corrections. Entries are dated and sourced. If you spot something that needs correction, email [email protected].